Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03129061 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Phase 1 study, sponsored by CellSight Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03129061 is a Phase 1 study that has completed, run by CellSight Technologies. The registered enrollment target is 15 participants.
The verdict
NCT03129061, a Phase 1 study, has completed, sponsored by CellSight Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a single-center cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohort 1 will be patients with unresectable or metastatic SCCHN cancer receiving standard of care (SOC) anti-PD-1 treatment and Cohort 2 will be neoadjuvant study participants who will receive one dose of anti-PD-1 treatment prior to tumor resection or radiation. Blood sampling and tissue biopsies will be collected from both cohorts and both cohorts will undergo two whole body PET(Positron Emission Tomography)/CT(Computed Tomography) imaging with \[18F\]F-AraG. First scan prior to initiating anti-PD-1 treatment and second scan post initiation of anti-PD-1 treatment in Cohort 1 and prior to tumor resection or radiation in Cohort 2
Interventions
- DRUG [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03129061
The ClinicalTrials.gov registry entry for NCT03129061 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CellSight Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy. is the first listed.
NCT03129061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03129061 about?
NCT03129061 is a clinical study titled "Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)". This is a single-center cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohort 1 will be patients with unresectable or metastatic SCCHN cancer receiving standard of care (SOC) anti-PD-1 treatment and Cohort 2 will be neoa...
What is the current status of trial NCT03129061?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-05-01. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT03129061?
The interventions under investigation include: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy. (DRUG).
Who is sponsoring clinical trial NCT03129061?
This trial is sponsored by CellSight Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.